Latest lecanemab data to be presented at the AD/PD™ c

/PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data...

Related Keywords

Sweden , Japan , Stockholm , Uppsala , Uppsala Lan , Barcelona , Comunidad Autonoma De Cataluna , Spain , Swedish , Oskar Bosson , Marwan Sabbagh , Michaelc Irizarry , Lons Schneider , Eric Mcdade , Parkinson Abbvie , Lars Lannfelt , Gunilla Osswald , Uppsala University , National Institutes Of Health , National Institute On , Drug Administration , Alzheimer Network Trials Unit Tau Nexgen , International Conference On Alzheimer , Devices Agency , Alzheimer Clinical Trial Consortium , Nasdaq Stockholm , International Conference , Professor Lars Lannfelt , Dominantly Inherited Alzheimer , Network Trials Unit , Tau Nexgen , Breakthrough Therapy , Fast Track , Biologics License Application , Medical Devices Agency , Inherited Alzheimer , Tau Nexgen Platform Trial , Anti Tau Antibody , Background Lecanemab , Systems Pharmacology Amyloid Platform , Multiscale Computational Modeling , Its Interaction , Month Study Evaluating Lecanemab , Early Alzheimer , Vice President Communications , Investor Relations , Clinical Trial Consortium , National Institute , National Institutes , Commercialization Agreement , Nasdaq Stockholm Mid Cap , Bioarctic , Health Care Amp Hospitals , Pharmaceuticals , Medical Pharmaceuticals , Biotechnology , Clinical Trials Amp Medical Discoveries ,